NYCELLO Intent to Use Trademark Application for Cell Therapy

ChangeBridge: Trademarks - Medical Services (Class 044)

Detected March 26th, 2026

Summary

The USPTO has received an intent-to-use trademark application for the mark NYCELLO. The application covers various cell therapy and immunotherapy preparations and related medical treatment services. The filing date was April 25, 2025.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has received an intent-to-use trademark application (TM99155713) for the mark NYCELLO. The application covers a range of goods and services, including cell therapy pharmaceutical preparations, immunotherapy preparations for cancer treatment, T-cell receptors, and medical services related to cell therapy and immunotherapy. The filing date for this application was April 25, 2025.

This filing represents a new potential brand entry into the cell therapy and immunotherapy market. While this is a trademark application and not a regulatory approval for the therapy itself, it indicates a commercial intent for these specific medical products and services. Companies operating in the cell therapy space should be aware of this new trademark filing as it may impact branding and market positioning in the future.

Source document (simplified)

← USPTO Trademark Applications

NYCELLO

Intent to Use TM99155713 Kind: intenttouse Mar 24, 2026

Abstract

Cell therapy pharmaceutical preparations; immunotherapy preparations for use in cancer treatment; T-cell receptors in the nature of pharmaceutical preparations for use in cancer treatment; pharmaceutical immunotherapy preparations comprising engineered T-cell receptors for use in cancer treatment; pharmaceutical immunotherapy preparations comprising genes encoding engineered T-cell receptors for use in cancer treatment; Cell therapy medical treatment services; medical services, namely, immunotherapy services; medical services, namely, medical treatment and immune-therapy comprising harvesting a patient's white blood cells, combining white blood cells with an engineered T-cell receptor therapeutic, transducing the white blood cells with the gene encoding the engineered T-cell receptor and infusion of the transduced white blood cells back into the patient